Lupin receives USFDA nod for Lorazepam Oral Concentrate

Tags: Companies
Drug firm Lupin today said it has received US health regulator's approval to market its generic Lorazepam Oral Concentrate, used for treating anxiety disorders, in the American market.

Lupin Pharmaceuticals Inc, a subsidiary of Lupin, has received final approval from US Food and Drug Administration (USFDA) for its Lorazepam Oral Concentrate USP, Lupin Ltd said in a statement.

The Mumbai-headquartered firm's product is a generic version of Roxane Inc's Lorazepam Intensol and is indicated for the management of anxiety disorders or for the short- term relief of the symptoms of anxiety or anxiety associated with depressive symptoms, it added.

According to IMS MAT September 2012 sales data, Lorazepam Oral Concentrate had annual US sales of nearly $10.7 million.

Lupin scrip closed at Rs 594 on the BSE, down 0.21 per cent from its previous close.

EDITORIAL OF THE DAY

  • Mergers apart, Sebi must also allow fund houses to offer diverse products

    The Securities and Exchange Board of India’s (Sebi’s) reported push for merger of open-ended mutual fund schemes is a logical step, as there is li

FC NEWSLETTER

Stay informed on our latest news!

TODAY'S COLUMNS

Arun Nigavekar

Can Hefa actually become a reality?

The ministry of human resource development (MHRD) is actively wo­rking ...

Rajgopal Nidamboor

Creativity is that divine luminosity

Creativity or ingenuity, isn’t a licence limited to ‘functioning’ minds ...

Dharmendra Khandal

No one's getting rich overnight by poaching

We often read in newspapers that tiger skin worth Rs ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture